Skip to content

Islatravir plus doravirine may offer new dual therapy option

Image from the livestream of Jean-Michel Molina at IAS 2019.

Trial vaccine could protect against HIV for more than five years

Daniel Stieh, presenting the ASCENT study, at IAS 2019. Photo by Liz Highleyman.

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds

Roland Landman at IAS 2019. Photo by Liz HIghleyman.

ADVANCE trial shows dolutegravir is highly effective in South Africa

Image from the livestream of Francois Venter at IAS 2019.

Three forms of PrEP stigma in Kenya

Daniel Were at IAS 2019. Photo by Gus Cairns.

PrEP implant could last well over a year

Randolph Matthews at IAS 2019. Photo by Liz Highleyman.

WHO endorses event-driven PrEP for gay men

Jean-Michel Molina at IAS 2019. Photo by Liz Highleyman.

South Africa saves $326 million on dolutegravir

Avatar_023/Shutterstock.com

Men accounted for two-thirds of HIV transmission in PopART prevention trial

William Probert at IAS 2019. Photo by Roger Pebody.